The emerging role of interleukin-1β in autoinflammatory diseases

Arthritis and Rheumatism

Volumn 63, Issue 2, 2011, Pages 314-324

  Lachmann, Helen J ^a   Quartier, Pierre ^b   So, Alexander ^c   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA;

ADULT ONSET STILL DISEASE; CINCA SYNDROME; GOUT; INFLAMMATORY DISEASE; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA;

EID: 79551657911     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30105     Document Type: Review

References (62)

1. Martinon F, Mayor A, Tschopp J,. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
2. Dinarello CA,. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
3. Glaser RL, Goldbach-Mansky R,. The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 2008; 8: 288-98.
4. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD,. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5.
5. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-8.
6. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581-92.
7. Hawkins PN, Lachmann HJ, McDermott MF,. Interleukin-1- receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348: 2583-4.
8. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-85.
9. Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008; 12: 8-16.
10. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52.
11. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58: 2432-42.
12. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
13. Kuemmerle-Deschner J, Blank N, Roesler J, Ramos E, Lachmann HJ, Hoyer JD, et al. Canakinumab (ACZ885), a new IL-1β blocking monoclonal antibody, provides sustained remission in patients with cryopyrin associated periodic fever syndrome (CAPS): results of an open label phase II study [abstract]. Ann Rheum Dis 2009; 68 Suppl III: iii366.
14. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010; 62: 258-67.
15. Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Hoyer J, Smith J, Leslie K, et al. Canakinumab provides rapid response and sustained remission in patients with cryopyrin associated periodic syndrome (CAPS) across different severity phenotypes [abstract]. Ann Rheum Dis 2010; 69 Suppl III: iii112.
16. Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 2008; 112: 1794-803.
17. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
18. Van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87: 301-10.
19. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-37.
20. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-44.
21. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
22. Verbsky JW, White AJ,. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
23. Kalliolias GD, Liossis SN,. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008; 17: 349-59.
24. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al, on behalf of the Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pediatrie (SOFREMIP) and the Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-8.
25. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
26. Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, et al. A phase II trial with canakinumab (ACZ885), a new IL-1-β blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis (SJIA) [abstract]. Ann Rheum Dis 2009; 68 Suppl III: iii170.
27. Lovell DJ, Giannini EH, Kimura Y, Li S, Hashkes PJ, Reiff AO, et al. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA) [abstract]. Arthritis Rheum 2007; 56 Suppl: S514-5.
28. Lovell DJ, Giannini EH, Kimura Y, Li SC, Hashkes PJ, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA) [abstract]. Arthritis Rheum 2009; 60 Suppl: S768.
29. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
30. Neogi T,. Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer? [editorial]. Arthritis Rheum 2010; 62: 2845-49.
31. Martinon F, Tschopp J,. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14: 10-22.
32. McDermott MF, Tschopp J,. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends Mol Med 2007; 13: 381-8.
33. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008; 105: 9035-40.
34. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-26.
35. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T,. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-8.
36. Donath MY, Weder C, Brunner A, Keller C, Whitmore J, Der K, et al. XOMA 052, a potential disease modifying anti-IL-1β antibody, shows sustained HbA1c reductions 3 months after a single injection with no increases in safety parameters in subjects with type 2 diabetes. Abstract 113-OR presented at 69th Annual Meeting of the American Diabetes Association, June 5-9, 2009, New Orleans, LA.
37. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84: 114-22.
38. Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, et al. Efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to canakinumab 300 mg s. c. preliminary study results [abstract]. Arthritis Rheum 2009; 60 Suppl: S299.
39. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15: 161-4.
40. Hoffman HM, Nadler DR, Brooks WP, Weinstein SP,. Rilonacept: long-term safety profile in patients with cryopyrin-associated periodic syndromes (CAPS) [abstract]. Arthritis Rheum 2009; 60 Suppl: S463.
41. Burger D, Dayer JM, Palmer G, Gabay C,. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20: 879-96.
42. Kapur S, Bonk ME,. Rilonacept (Arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T 2009; 34: 138-41.
43. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R67.
44. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008; 47: 555-6.
45. Pontikaki I, Gerloni V, Gattinara M, Hila A, Donati C, Fantini F,. Anakinra in systemic juvenile idiopathic arthritis (SoJIA) non responsive to anti-TNF [abstract]. Ann Rheum Dis 2008; 67 Suppl II: ii271.
46. Punaro L, Gotte AC, Blankenship DM, Stoll ML, Allantaz F, Pascual V,. Clinical and microarray follow-up of systemic-onset juvenile idiopathic arthritis (SOJIA) patients treated with anakinra [abstract]. Arthritis Rheum 2008; 58 Suppl: S943.
47. Quartier P, Allantaz F, Cimaz R, Pillet P, Duquesne A, Mogenet A, et al. A multicentric, double-blind trial of anakinra versus placebo in systemic-onset juvenile idiopathic arthritis (ANAJIS trial): efficacy and tolerance over 12 months [abstract]. Arthritis Rheum 2008; 58 Suppl: S632.
48. De Koning HD, Bodar EJ, van der Meer JW, Simon A,. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-48.
49. Eiling E, Moller M, Kreiselmaier I, Brasch J, Schwarz T,. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 2007; 57: 361-4.
50. Crouch R, Akhras V, Sarkany R,. Schnitzler's syndrome: successful treatment with anakinra. Australas J Dermatol 2007; 48: 178-81.
51. Dybowski F, Sepp N, Bergerhausen HJ, Braun J,. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 2008; 26: 354-7.
52. Devlin LA, Wright G, Edgar JD,. A rare cause of a common symptom, anakinra is effective in the urticaria of Schnitzler syndrome: a case report. Cases J 2008; 1: 348.
53. Kluger N, Riviere S, Guillot B, Bessis D,. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome. Acta Derm Venereol 2008; 88: 287-8.
54. Frischmeyer-Guerrerio PA, Rachamalla R, Saini SS,. Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol 2008; 100: 617-9.
55. Gilson M, Abad S, Larroche C, Dhote R,. Treatment of Schnitzler's syndrome with anakinra. Clin Exp Rheumatol 2007; 25: 931.
56. Schneider SW, Gaubitz M, Luger TA, Bonsmann G,. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 2007; 56: S120-2.
57. Wastiaux H, Barbarot S, Gagey-Caron V, Berthelot JM, Hamidou M, Stalder JF,. Schnitzler syndrome: a dramatic improvement with anakinra. J Eur Acad Dermatol Venereol 2009; 23: 85-7.
58. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA,. Resistant BehÃet disease responsive to anakinra. Ann Intern Med 2008; 149: 284-6.
59. Bilginer Y, Ayaz NA, Ozen S,. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and BehÃet's disease. Clin Rheumatol 2010; 29: 209-10.
60. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C,. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 2006; 45: 491-2.
61. Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E,. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 2008; 75: 622-4.
62. Delluc A, Limal N, Puechal X, Frances C, Piette JC, Cacoub P,. Efficacy of anakinra, an IL-1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008; 67: 278-9.